- Page 2 and 3:
This publication was developed in t
- Page 4 and 5:
1.5 Events ........................
- Page 6 and 7:
2.42 PHARM-HOLDING ................
- Page 8 and 9:
1 PART 1: MARKET RESEARCH1.1 Indust
- Page 10 and 11:
The Russian pharmaceutical market i
- Page 12 and 13:
Imported/localized drugs sales rati
- Page 14 and 15:
In 2020, the share of original drug
- Page 16 and 17:
1.1.2 Commercial segment of the Rus
- Page 18 and 19:
1.1.3 Drug reimbursement segmentAcc
- Page 20 and 21:
1.1.4 Segment of purchases of drugs
- Page 22 and 23:
1.1.5 Dietary supplements segmentAc
- Page 24 and 25:
The development of the innovative d
- Page 26 and 27:
Dynamics of pharmaceutical products
- Page 28 and 29:
§ the term of the SPIC has been ex
- Page 30 and 31:
The Pharma-2030 Strategy elaboratio
- Page 32 and 33:
presence of viral RNA and antibodie
- Page 34 and 35:
§ training system in the field of
- Page 36 and 37:
counter external risks (for example
- Page 38 and 39:
1.3.2 The Pavlov First Saint Peters
- Page 40 and 41:
1.3.3 North-Western State Medical U
- Page 42 and 43:
1.3.4 Military Medical Academy name
- Page 44 and 45:
1.3.6 Saint-Petersburg State Instit
- Page 46 and 47:
1.3.7 Peter the Great St. Petersbur
- Page 48 and 49:
1.3.9 Saint-Petersburg Medico-Socia
- Page 50 and 51:
1.4.2 Almazov National Medical Rese
- Page 52 and 53:
1.4.4 Institute of Cytology RASInst
- Page 54 and 55:
1.4.6 Kashkin Research Institute of
- Page 56 and 57:
1.4.8 Research Institute of Hygiene
- Page 58 and 59:
1.4.10 Saint-Petersburg Pasteur Ins
- Page 60 and 61:
Contact informationBekhtereva Str.,
- Page 62 and 63:
The Institute has Influenza and ARD
- Page 64 and 65:
1.4.14 V. M. Gorbatov Federal Resea
- Page 66 and 67:
1.5 Events1.5.1 Events calendarDate
- Page 68 and 69:
1.5.2.2 Nordic Life Science DaysNor
- Page 70 and 71:
1.5.2.4 HealthBIOThe HealthBIO even
- Page 72 and 73:
1.5.2.6 BioJapanBioJapan has played
- Page 74 and 75:
1.5.2.8 CPhI WorldwideCPhI is an es
- Page 76 and 77:
1.5.2.10 INTERPHEX Japan 2021INTERP
- Page 78 and 79:
1.5.3.2 IPhEB RussiaIPhEB Russia is
- Page 80 and 81:
1.6 Clusters and associations1.6.1
- Page 82 and 83:
1.6.3 Cluster of medical, environme
- Page 84 and 85:
1.7 Cases and success stories1.7.1
- Page 86 and 87:
1.8 Information sources1.8.1 Strate
- Page 88 and 89:
§ DSM Group. Analytical report “
- Page 90 and 91:
2.2 ALKOR BIOCompany profileThe St.
- Page 92 and 93: 2.4 AMBERCompany profileAmber Group
- Page 94 and 95: 2.6 AVENACompany profileAvena compa
- Page 96 and 97: 2.8 BELKOZINCompany profileBelkozin
- Page 98 and 99: 2.10 BIOCADCompany profileBiocad is
- Page 100 and 101: 2.12 BIOPHARMOSCompany profileBioPh
- Page 102 and 103: 2.14 BIOTECHCompany profileBiotech
- Page 104 and 105: 2.16 CYTOMEDCompany profileCytomed
- Page 106 and 107: 2.18 EKVUSCompany profile“Ekvus
- Page 108 and 109: 2.20 FARMAKOGENCompany profileFarma
- Page 110 and 111: 2.22 FRAMEBIOTEKCompany profileFram
- Page 112 and 113: 2.24 GEROPHARMCompany profileGeroph
- Page 114 and 115: 2.26 GROTEXCompany profileSolopharm
- Page 116 and 117: 2.28 HARMSCompany profileHistory of
- Page 118 and 119: 2.30 LEKKERCompany profileThe histo
- Page 120 and 121: 2.32 NEPHRONCompany profileResearch
- Page 122 and 123: 2.34 NIKACompany profileNika Factor
- Page 124 and 125: 2.36 PHARM. ASSOCIATION NAMED FOR P
- Page 126 and 127: 2.38 PHARMA VAMCompany profilePharm
- Page 128 and 129: 2.40 PHARMAKOR PRODUCTIONCompany pr
- Page 130 and 131: 2.42 PHARM-HOLDINGCompany profilePh
- Page 132 and 133: 2.44 PHARMSYNTHEZCompany profilePha
- Page 134 and 135: 2.46 PPDPCompany profileEnterprise
- Page 136 and 137: 2.48 RESEARCH INSTITUTE OF INNOVATI
- Page 138 and 139: 2.50 SEVERNAIA ZVEZDACompany profil
- Page 140 and 141: 2.52 VITAL DEVELOPMENT CORPORATIONC
- Page 144: 144RUSSIAN-FINNISH LIFE SCIENCE IND